Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 5Rhabdomyosarcoma 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Sezary Syndrome 1Sarcoma, Ewing 1Rhabdoid Tumor 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Temozolomide 26Magnetic Resonance Spectroscopy 19Etoposide 12Cyclophosphamide 12Radiotherapy 11Bevacizumab 10Filgrastim 9Biopsy 8Carboplatin 7X-Rays 6Thiotepa 6Specimen Handling 6Phantoms, Imaging 6Cisplatin 6Carmustine 6Nuclear Medicine Department, Hospital 5Nivolumab 5Irinotecan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4olaparib 3etoposide phosphate 3Vincristine 3Surveys and Questionnaires 3Lapatinib 3Gadolinium DTPA 3Azacitidine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × Tacrolimus × CNS × Clear all
NCT04521946 2024-10-26

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

M.D. Anderson Cancer Center

Phase 1 Withdrawn
CNS

Choroid Plexus Carcinoma, Brain Neoplasms, Ependymoma, Glioma, Medulloblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡